SerF-ADJNCT07904156
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
2-Year Recurrence-Free Survival (RFS) Rate
Timeframe: 2-year
Secondary (2)
Overall Survival (OS)
Incidence and Severity of Adverse Events
Arms and interventions
Serplulimab Plus FruquintinibExperimental
Participants will start adjuvant treatment within 12 weeks after surgery. Serplulimab 300 mg will be administered by intravenous infusion every 3 weeks for up to 17 cycles. Fruquintinib 5 mg will be taken orally once daily for 14 days, followed by 7 days off, for a total of 12 weeks.
ObservationNo intervention
Participants will receive no adjuvant study treatment after surgery. They will undergo scheduled clinical and imaging assessments every 12 weeks to monitor for disease recurrence and survival.
Drugs: Serplulimab + Fruquintinib